刘君,汪建云,张宁,刘焕,巩诗彤,安晓雷

• 1:徐州市中心医院

摘要(Abstract)：

目的 评估A型肉毒毒素（BTX-A）联合甲钴胺治疗三叉神经痛的临床效果及其对患者心理情绪的影响。方法 纳入徐州市中心医院2021-01—2023-12收治的40例三叉神经痛患者为观察对象，随机分成对照组和观察组，每组20例。对照组予以A型肉毒素注射治疗，观察组予以A型肉毒素和甲钴胺联合治疗。2组均在治疗2、4、12周后观察疗效，采用视觉模拟评分量表（VAS评分）对2组患者进行评估，应用汉密尔顿焦虑量表（HAMA）和匹兹堡睡眠质量指数（PSQI）对患者治疗后第12周的焦虑和睡眠情况进行评估。结果 观察组和对照组治疗前VAS评分差异无统计学意义（P>0.05），治疗后2、4、12周2组VAS评分均低于治疗前（P<0.05），观察组明显低于对照组，差异有统计学意义（P<0.05）,2组VAS评分变化趋势也存在统计学差异（P<0.05）。观察组治疗后2、4、12周的有效率高于对照组，差异有统计学意义（P<0.05）。治疗12周，2组HAMA和PSQI评分均下降（P<0.05），与治疗前相比差异均有统计学意义（P<0.05）。观察组治疗后12周HAMA及PSQI评分较对照组更低，差异有统计学意义（P<0.05）。结论 A型肉毒素联合甲钴胺治疗三叉神经痛患者疗效确切，能减轻焦虑及睡眠状况，改善心理情绪。

关键词(KeyWords)： 三叉神经痛;A型肉毒素;甲钴胺;心理情绪;焦虑;睡眠状况

Abstract:

Keywords:

基金项目(Foundation): 徐州市科技局基金项目(编号:KC22175)

作者(Author): 刘君,汪建云,张宁,刘焕,巩诗彤,安晓雷

参考文献(References)：

• [1] NADERI Y,RAD M,SADATMOOSAV A,et al. Compared tooxcarbazepine and carbamazepine,botulinum toxin type A is auseful therapeutic option for trigeminal neuralgia symptoms:Asystematic review[J]. Clin Exp Dent Res,2024,10(2):e882.
• [2] ALLAM A K,LARKIN M B,SHARMA H,et al. Trigeminal andGlossopharyngeal Neuralgia[J]. Neurol Clin,2024,42(2):585-598.
• [3] PENG Y,ZOU C,LI Y,et al. Balloon Pressure and ClinicalEffectiveness of Percutaneous Microballoon Compression in theTreatment of Primary Trigeminal Neuralgia[J]. Pain Physician,2024,27(3):E345-E353.
• [4] WU C J,SHEN J H,CHEN Y,et al. Comparison of two differentformulations of botulinum toxin a for the treatment of blepharospasmand hemifacial spasm[J]. Turk Neurosurg,2011,21(4):625-629.
• [5] WAN Q. Botulinum toxin type A ameliorates rat dorsal root ganglianeuron pyroptosis in postherpetic neuralgia by upregulatingcathelicidin antimicrobial peptide to inhibit neutrophil elastase[J].Chem Biol Drug Des,2024,103(1):14406.
• [6] TERESHKO Y,ENRICO B,CHRISTIAN L,et al. Botulinum toxintype A for genitofemoral neuralgia:A case report[J]. FrontNeurol,2023,14(1):1228098.
• [7] SUTHER K R,HOPP E,SMEVIK B,et al. Can visual analoguescale be used in radiologic subjective image quality assessment[J].Pediatr Radiol,2018,48(11):1567-1575.
• [8] SUN B,ZHANG C,HUANG K,et al. The white matter characteristicof the genu of corpus callosum coupled with pain intensity andnegative emotion scores in patients with trigeminal neuralgia:amultivariate analysis[J]. Front Neurosci,2024,18:1381085.
• [9] WASKITHO A,YAMAMOTO Y,RAMAN S,et al. PeripherallyAdministered Botulinum Toxin Type A Localizes Bilaterally inTrigeminal Ganglia of Animal Model[J]. Toxins,2021,13(10):704.
• [10] YOSHIDA K. Effects of Botulinum Toxin Type A on Pain amongTrigeminal Neuralgia,Myofascial Temporomandibular Disorders,and Oromandibular Dystonia[J]. Toxins,2021,13(9):605.
• [11] WANG Q,LI F. Botulinum toxin type A in combination withpulsed radiofrequency to the semilunar ganglion of the trigeminalnerve for trigeminal trophic syndrome[J]. J Dermatol,2021,48(8):e388-e389.
• [12] SPAGNA A,ATTAL N. Botulinum toxin A and neuropathic pain:An update[J]. Toxicon,2023,232:107208.
• [13] TERESHKO Y,VALENTE M,BELGRADO E,et al. TheTherapeutic Effect of Botulinum Toxin Type A on TrigeminalNeuralgia:Are There Any Differences between Type 1 versusType 2 Trigeminal Neuralgia?[J]. Toxins,2023,15(11):654.
• [14] REYES-LONG S, ALFARO-RODRíGUEZ A, CORTESALTAMIRANO J L,et al. The Mechanisms of Action of BotulinumToxin Type A in Nociceptive and Neuropathic Pathways inCancer Pain[J]. Curr Med Chem,2021,28(15):2996-3009.
• [15] CHO J H,SON J Y,JU J S,et al. Cellular mechanisms mediatingthe antinociceptive effect of botulinum toxin A in a rodent modelof trigeminal irritation by a foreign body[J]. J Pain,2022,23(12):2070-2079.
• [16] CHEN W J,NIU J Q,CHEN Y T,et al. Unilateral facial injection ofBotulinum neurotoxin A attenuates bilateral trigeminal neuropathicpain and anxiety-like behaviors through inhibition of TLR2-mediatedneuroinflammation in mice[J]. J Headache Pain,2021,22(1):38.
• [17] RAN G L,LI Y P,LU L C,et al. Disease-modifying therapies fordiabetic peripheral neuropathy:A systematic review andmeta-analysis of randomized controlled trials[J]. J DiabetesComplications,2024,38(2):108691.
• [18] SAWANGJIT R,THONGPHUI S,CHAICHOMPU W,et alEfficacy and Safety of Mecobalamin on Peripheral Neuropathy:ASystematic Review and Meta-analysis of Randomized ControlledTrials[J]. J Alternat Complement Med,2020,26(12):1117-1129.
• [19] ALYOUBI R A,ALSHAREEF A A,ALDUGHAITHER S M,et al.Efficacy and Safety of Mirogabalin Treatment in Patients withDiabetic Peripheral Neuropathic Pain:A Systematic Review andMeta-analysis of Randomized Controlled Trials[J]. Int J ClinPract,2021,75(5):13744.
• [20] FISHER R,CLARKSON E. Medication Management of NeuropathicPain Disorders[J]. Dental Clin North Am,2024,68(1):121-131.
• [21] CHEN E Y,BEUTLER S S,KAYE A D,et al. Mirogabalin as aNovel Gabapentinoid for the Treatment of Chronic PainConditions:An Analysis of Current Evidence[J]. Anesth PainMed,2021,11(6):e121402.
• [22] RAN G L,LI Y P,LU L C,et al. Disease-modifying therapies fordiabetic peripheral neuropathy:A systematic review andmeta-analysis of randomized controlled trials[J]. J DiabetesComplications,2024,38(2):108691.
• [23] CHAPLAN S R,GUO H Q,LEE D H,et al. Neuronal hyperpolarization-activated pacemaker channels drive neuropathic Pain[J]. J Neurosci,2003,23(4):1169-1178.
• [24] SALL HANSSON K,LINDQVIST G,STENING K,et al. SteningKent Efficacy of mecobalamin(vitamin B12)in the treatment oflong-term pain in women diagnosed with fibromyalgia:protocolfor a randomised,placebo-controlled trial[J]. BMJ Open,2023,13(3):066987.
• [25] ZHANG M,HAN W,HU S,et al. Methylcobalamin:A PotentialVitamin of Pain Killer[J]. Neural Plast,2013,2013:424651.
• [26] KOPRUSZINSKI C M,REIS R C,BRESSAN E,et al. Vitamin Bcom-plex attenuated heat hyperalgesia following infraorbital nerveconstriction in rats and reduced capsaicin in vivo and in vitroeffects[J]. Eur J Pharmacol,2015,762:326-332.